New hope for Tough-to-Treat breast cancer after standard therapy fails
NCT ID NCT06408168
Summary
This study tested whether combining the drug repotrectinib with or without fulvestrant could help control metastatic lobular breast cancer in people whose disease progressed after standard hormone therapy. The trial enrolled 6 participants with hormone-positive, HER2-negative metastatic lobular carcinoma who had previously received specific targeted treatments. The study was terminated early, and researchers were measuring how long the treatment could keep the cancer from worsening.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR-POSITIVE HUMAN EPIDERMAL GROWTH FACTOR 2-NEGATIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.